An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Inclusion Criteria:

1. Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria
2. 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening
3. inadequate response to a ≥1 month treatment with topical medications
4. Atopic dermatitis covering ≥10% of the body surface area
5. EASI score ≥16
6. Validated Investigator Global Assessment (VIGA) ≥3
7. Use of emollient(s) at least 2x daily for 1 week prior to baseline
8. Negative coronavirus disease (COVID)-19 results at screening

Exclusion Criteria:

1. Uncontrolled moderate-to-severe asthma
2. Uncontrolled diabetes
3. Stage III or IV cardiac failure
4. Severe renal condition
5. Major surgery within 8 weeks of screening
6. Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline
7. Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline
8. Received live or live-attenuated vaccine within 4 weeks of baseline
9. Prior receipt of RPT193